An observational study in Pulmonary Hypertension, sponsored by RenJi Hospital. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by RenJi Hospital · Observational
Primary objective: To establish a non-invasive diagnostic model for pulmonary hypertension based on laboratory indicators and echocardiographic parameters.
Secondary objectives: To investigate the correlations between laboratory test indicators and echocardiographic data, and to develop new parameters based on preliminary analysis to assist in the diagnosis of pulmonary hypertension
Data collection:
Collect vital signs (age, sex, etc.), clinical laboratory tests (complete blood count, biochemistry, BNP, D-dimer, and related derived parameters), and echocardiographic data from both the control group and pulmonary hypertension (PH) patients.
Obtain hemodynamic data measured via right heart catheterization (RHC) in PH patients.
Model development:
Construct a clinical diagnostic model using laboratory and echocardiographic data.
Fit hemodynamic parameters of PH patients based on their laboratory indicators, then assess the hemodynamic status using the fitted parameters and compare with actual measurements.
Secondary analyses:
Investigate correlations between echocardiographic parameters and laboratory test indicators in PH patients.
Identify core variables to develop novel diagnostic parameters and evaluate their diagnostic performance.
1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.
This study's enrollment of 199 is above the median of 116 across 386 observational studies indexed under Hypertension, Pulmonary.
Browse Hypertension, Pulmonary studies →RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with all types of PH
No gender restrictions; age >18 years.
Availability of complete RHC records, transthoracic echocardiography (TTE), and laboratory test results (echocardiography and lab tests must be performed within one month before or after RHC).
Exclusion Criteria:
Active or history of malignancy (or Malignant tumors if referring to current cases)
Hematologic disorders
people with pulmonary hypertension
AUC
the area under ROC curve
Time frame: from 1 Jan 2025 to 30 Apr 2025
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RenJi Hospital